{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:50:38Z","timestamp":1789901438060,"version":"4.0.1"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":2503,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[1997,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aspirin is only modestly effective in the secondary prevention after cerebral ischemia. Studies in other vascular disorders suggest that anticoagulant drugs in patients with cerebral ischemia of presumed arterial (noncardiac) origin might be more effective. The aim of the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) therefore was to compare the efficacy and safety of 30 mg aspirin daily and oral anticoagulation (international normalized ratio [INR] 3.0\u20134.5). Patients referred to a neurologist in one of 58 collaborating centers because of a transient ischemic attack or minor ischemic stroke (Rankin grade $3) were eligible. Randomization was concealed, treatment assignment was open, and assessment of outcome events was masked. The primary measure of outcome was the composite event \u201cdeath from all vascular causes, nonfatal stroke, nonfatal myocardial infarction, or nonfatal major bleeding complication.\u201d The trial was stopped at the first interim analysis. A total of 1,316 patients participated; their mean follow\u2010up was 14 months. There was an excess of the primary outcome event in the anticoagulated group (81 of 651) versus 36 of 665 in the aspirin group (hazard ratio, 2.3; 95% confidence interval [CI], 1.6\u20133.5). This excess could be attributed to 53 major bleeding complications (27 intracranial; 17 fatal) during anticoagulant therapy versus 6 on aspirin (3 intracranial; 1 fatal). The bleeding incidence increased by a factor of 1.43 (95% CI, 0.96\u20132.13) for each 0.5 unit increase of the achieved INR. Anticoagulant therapy with an INR range of 3.0 to 4.5 in patients after cerebral ischemia of presumed arterial origin is not safe. The efficacy of a lower intensity anticoagulation regimen remains to be determined.<\/jats:p>","DOI":"10.1002\/ana.410420606","type":"journal-article","created":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T15:10:08Z","timestamp":1104592208000},"page":"857-865","source":"Crossref","is-referenced-by-count":366,"title":["A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin"],"prefix":"10.1002","volume":"42","member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatclet therapy\u20141: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.60.2.197"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90608-6"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110313251801"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92154-6"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199007193230302"},{"key":"e_1_2_1_8_2","first-page":"499","article-title":"Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of longterm oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardialinfarction","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198209163071201"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106273242606"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.19.8.1043"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92358-Z"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1055\/s-0038-1657886","article-title":"Questions and answers on prothrombin time standardisation in oral anticoagulant control","volume":"54","author":"Loeliger EA","year":"1985","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)01109-9"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.19.5.604"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.20.6.828"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651587"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.6.2892"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life\u2010tables","volume":"34","author":"Cox DR","year":"1972","journal-title":"J R Stat Soc [B]"},{"key":"e_1_2_1_20_2","unstructured":"Egret statistical package. Seattle: Statistics and Epidemiology Research Corporation 1990"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(96)00020-4"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507063330103"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507063330102"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.10.2073"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.4.649"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.24.4.554"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90955-O"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90161-9"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000107841"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608223350802"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)03487-3"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-11-199606010-00004"},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-0038-1650514","article-title":"Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants","volume":"76","author":"van der Meer FJM","year":"1996","journal-title":"Thromb Haemost"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.410420606","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.410420606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T05:33:15Z","timestamp":1734845595000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.410420606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1997,12]]}},"alternative-id":["10.1002\/ana.410420606"],"URL":"https:\/\/doi.org\/10.1002\/ana.410420606","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,12]]}}}